Diagnosis and Management of Prediabetes
JAMA · 11.04.2023 · 329 (14) · 1206
DOI: 10.1001/jama.2023.4063 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA, erschienen am 11.04.2023. Verfasst von Justin B Echouffo-Tcheugui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Prediabetic State, Healthy Lifestyle. Die Arbeit wurde bisher 477-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Importance Prediabetes, an intermediate stage between normal glucose regulation and diabetes, affects 1 in 3 adults in the US and approximately 720 million individuals worldwide. Observations Prediabetes is defined by a fasting glucose level of 100 to 125 mg/dL, a glucose level of 140 to 199 mg/dL measured 2 hours after a 75-g oral glucose load, or glycated hemoglobin level (HbA 1C ) of 5.7% to 6.4% or 6.0% to 6.4%. In the US, approximately 10% of people with prediabetes progress to having diabetes each year. A meta-analysis found that prediabetes at baseline was associated with increased mortality and increased cardiovascular event rates (excess absolute risk, 7.36 per 10 000 person-years for mortality and 8.75 per 10 000 person-years for cardiovascular disease during 6.6 years). Intensive lifestyle modification, consisting of calorie restriction, increased physical activity (≥150 min/wk), self-monitoring, and motivational support, decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period. Metformin decreased the risk of diabetes among individuals with prediabetes by 3.2 cases per 100 person-years during 3 years. Metformin is most effective for women with prior gestational diabetes and for individuals younger than 60 years with body mass index of 35 or greater, fasting plasma glucose level of 110 mg/dL or higher, or HbA 1c level of 6.0% or higher. Conclusions and Relevance Prediabetes is associated with increased risk of diabetes, cardiovascular events, and mortality. First-line therapy for prediabetes is lifestyle modification that includes weight loss and exercise or metformin. Lifestyle modification is associated with a larger benefit than metformin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Baltimore, Maryland.
- Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora.
- Department of Endocrinology, Peking University People's Hospital, Xicheng District, Beijing, China.
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Echouffo-Tcheugui, J. B., Perreault, L., Ji, L., & Dagogo-Jack, S. (2023). Diagnosis and Management of Prediabetes. JAMA, 329(14), 1206. https://doi.org/10.1001/jama.2023.4063
Vancouver
Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and Management of Prediabetes. JAMA. 2023;329(14):1206. doi:10.1001/jama.2023.4063
BibTeX
@article{EchouffoTcheugui2023,
author = {Echouffo-Tcheugui, Justin B and Perreault, Leigh and Ji, Linong and Dagogo-Jack, Sam},
title = {Diagnosis and Management of Prediabetes},
journal = {JAMA},
year = {2023},
volume = {329},
number = {14},
pages = {1206},
doi = {10.1001/jama.2023.4063}
}
EUVIMED